Podcasts about csl behring

HFA Symposium is this weekend, and we have CEO Dan Kelsey on the podcast to tell us all about it! Plus, a gene therapy segment with the fantastic Brendan Hayes about what she's hearing in the community about gene therapy for hemophilia B.    Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information. Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

This episode covers: Cardiology This Week: A concise summary of recent studies Relevance and management of ventricular ectopic beats  Lp(a) in cardiovascular risk management Mythbusters: A vegetarian diet lowers cardiovascular risk Host: Susanna Price Guests: Carlos Aguiar, Thomas Deneke, Kausik Ray Want to watch that episode? Go to: https://esc365.escardio.org/event/1802 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Thomas Deneke, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Kausik Ray declared to have potential conflicts of interest to report: research grants from Amarin, Amgen, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Regeneron, and Sanofi, consultant for Abbott, Amarin, Amgen, AstraZeneca, Bayer, Biologix, Boehringer Ingelheim, Cargene Therapeutics, CRISPR, CSL Behring, Eli Lilly and Company, Esperion, Kowa Pharmaceuticals, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Therapeutics, Silence Therapeutics, Vaxxinity, and Viatris, honoraria for lectures from Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Biologix Pharma, Sanofi, Amgen, Esperion, Daiichi Sankyo, Macleod and stock options New Amsterdam Pharma, Pemi 31, SCRIBE Therapeutics. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Patrick chats with NBDF CEO, Phil Gattone, after his first Washington Days! Plus, Dr. Nathan Connell gives a terrific ASH Recap full of the latest research and development in bleeding disorders and Amy speaks with FLOW co-host, Jessica Richmond about women with bleeding disorders.    Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information. Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

Hereditary angioedema (HAE) is a rare condition often due to reduced levels C1-inhibitor, which is a protein involved in various physiological processes in plasma, most notably with the complement system. C1-inhibitor also binds and inhibits plasma kallikrein and factor XIa, thereby affecting bradykinin production. It is believed that the disruptions of these processes cause fluid to leak from the blood to connective tissue, leading to HAE attacks. Owing to its rarity, HAE is often poorly recognized, leading to misdiagnoses and significant diagnostic delays. Being aware of the early signs and symptoms of this condition can lead to faster diagnosis and the use of effective therapies.This program is supported by independent medical education grants from Takeda. To earn CME credit please visit https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/lessons/consider-rare-suspecting-and-diagnosing-hereditary-angioedema-module/  Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in primary care, pediatrics, emergency care, otolaryngology, gastroenterology, and dermatology .Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:- Describe the early symptoms of HAE and its clinical relevance.- Apply best practices to diagnose HAE more efficiently to reduce diagnostic delays. Faculty Jonathan A Bernstein, MDProfessor of MedicineUniversity of Cincinnati Department of Internal MedicineDivision of Immunology, Allergy SectionPartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Bernstein discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomarinGrant/Research Support: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomariSpeaker's Bureau: PharmingPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

We celebrate Rare Disease Day because we love our Rares! Also, folks from WHF join us to share their comprehensive summit and the gene therapy segment is back with a new host and Dr. Mark Kay and genetic counselor, Kaylee Dollerschell.   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information. Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter  

Host: Emer Joyce Guest: Gilles Montalescot Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1798?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Gilles Montalescot has declared to have potential conflicts of interest to report: research funds for Action Groupe or honoraria from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Dual antiplatelet therapy in 2025 Optimal communication with patients Snapshots Host: Emer Joyce  Guests: Carlos Aguiar, Michelle Kittleson, Gilles Montalescot Want to watch that episode? Go to: https://esc365.escardio.org/event/1798   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Emer Joyce, Michelle Kittleson and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Gilles Montalescot has declared to have potential conflicts of interest to report: research funds for Action Groupe or honoraria from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This podcast is sponsored by CSL Behring, manufacturer of Hizentra, subcutaneous immune globulin. In this episode, we will discuss Melaine's journey with PI, from her experience with IVIG, to her switch to subcutaneous IG, and what that meant in terms of self-administering her treatment at home. Melaine enjoys cycling, gardening, travel and she's also living with primary immunodeficiency or PI. Melaine will be sharing her story and also providing some information about Hizentra, for which she is a patient advocate. Patient advocates are not healthcare professionals or medical experts. For medical questions or advice, please contact your physician. Patient advocates are compensated by CSL Behring, LLC, for their time and/or expenses. Support the show

This podcast has been supported by CSL Behring. Bronchiectasis is a multifaceted condition with unique diagnostic and treatment considerations, presenting significant challenges for healthcare professionals. Join leading respiratory experts as they discuss bronchiectasis and the latest insights on managing inflammation in rare lung diseases.   Topics covered include: Advances in the epidemiology of bronchiectasis and its prevalence in chronic obstructive pulmonary disease and alpha 1 antitrypsin deficiency Recognising symptoms and identifying risk factors for recurrent exacerbations Diagnostic approaches, including the use of CT scans and laboratory tests Evidence-based treatment strategies and measures to prevent exacerbations

Patrick sits down with Jonathan Cappiello, an ultra-rare who hosts the podcast, 1 out of 20 (who also has a connection to Ryan White!). Plus, our final Gene Therapy segment of the year and those WHF USA announcements. All that and more on BloodStream!   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information.   It's a Whole New World brought to you by @CSLBehring.    The 1 out of 20 Podcast featuring PJL   Check out season 14 of Stop the Bleeding!   To learn more about our advocacy digital storytelling platform, Voices for Policy Change, head over to www.bleeding.org  

On the latest Gene Therapy segment, we host Blood Brothers Rick Starks, Colin Johnston, Bobby Wiseman for a roundtable discussion to hear their unique thoughts about the gene therapy landscape. We also honor Jess McClean (Page)'s life and her contribution to the bleeding disorder community.   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information.   It's a Whole New World brought to you by @CSLBehring.    Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter

Alternative Funding Programs are a nightmare new insurance tactic that has experts concerned. We've got Zack Duffy and Roland Lamy from the Hemophilia Alliance to break it down and tell you what to look out for. Plus, HFA's Project ECHO and the latest Gene Therapy segment, all about Myths and Misconceptions.  Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   Want more information on Alternate Funding Programs? Roland said to Google it.  But, here's some more stuff: AFP White Paper The Present and Future of Alternative Funding Programs for Specialty Drugs HFA Project ECHO: Recognition and Care of Women with Bleeding Disorders Oct 28 2024, 12:00 pm - 1:00 pm EST   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information. Genentech Patient Foundation is dedicated to making sure that people with hemophilia A can get access to treatment. No matter what type of health insurance you have, and even if you have none at all, there may be some potential options available to help you afford your medicine. To learn more about these resources and find out if you are eligible, visit www.HemophiliaAccess.com Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter 

In this special Youth Advocacy Month episode, join host Kobe as they sit down with HAEA Youth Advocacy Network Regional Leaders, Ally and Luke, to discuss their impactful experiences as young advocates during HAEA's Capitol Hill Day and advocacy training workshops. Ally and Luke share what it's like to participate in legislative visits, why it's crucial for young people to be involved in advocacy, and how their passion for legislative change drives their work in the HAE community. As seasoned advocates, they open up about their journey, the challenges they've faced, and the lasting impact they aim to make through their advocacy efforts. Tune in to be inspired by their dedication to making a difference and learn how you, too, can take action for the HAE community. This is a must-listen episode for young people ready to amplify their voices and lead the way in legislative advocacy! This youth produced podcast is brought to you thanks to the support of the Hereditary Angioedema Association, a patient advocacy organization serving the needs of the HAE patient and caregiver community. To learn more about the HAEA and access our incredible support network, visit, ⁠⁠⁠www.haea.org⁠⁠⁠. Thank you to our sponsors CSL Behring and ⁠Takeda⁠⁠⁠.

Coming to you LIVE from NBDF's Bleeding Disorder conference, Patrick is with CEO Phil Gattone right after Opening Session. A walk and talk you don't wanna miss! Also, hear how HTCs have operationally aligned to administer gene therapy with Zack Duffy and Roland Lamy from the Hemophilia Alliance on the latest Gene Therapy segment. Plus, an interview with Janet Brewer from CHES.   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information.   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

In this episode of the #BeyondHAE podcast, hosted by Youth Leadership Council Member Noah, Zach shares his journey with HAE, which began when he attended his first HAEA event at the young age of 9. Thirteen years later, Zach has built lifelong friendships and developed essential advocacy skills that have shaped who he is today. Known by many for his regular involvement in HAEA programs and events, Zach discusses living with HAE, the importance of taking his medication on time, and how he manages HAE in his daily life. Don't miss this insightful installment of the #BeyondHAE Day in the Life Interview Series. This youth produced podcast is brought to you thanks to the support of the Hereditary Angioedema Association, a patient advocacy organization serving the needs of the HAE patient and caregiver community. To learn more about the HAEA and access our incredible support network, visit, ⁠⁠⁠www.haea.org⁠⁠⁠. Thank you to our sponsors CSL Behring and ⁠Takeda⁠⁠⁠.

As a rare condition, understanding the root cause of Hereditary Angioedema (HAE) is crucial for improving patient management and care. On this episode of the HAE Speaks podcast, doctors Raffi Tachdjian, MD, MPH and Jay Kashkin, MD, dive deep into the critical role of factor XIIa on the HAE pathway. For more information, please visit www.haea.org. We would like to thank CSL Behring for sponsoring this episode!

During the month of August we will be enjoying some summer weather and taking a break from recording new episodes. To satiate your thirst we will be re-releasing the hottest episodes of the year, every week, for you to enjoy with a Mai Tai by the pool like David will be.In this re-release episode from February, I turn the podcasting tables on my guest Catherine O'Connell, who is host and cohost of two fantastic podcasts; Lawyer On Air and Jandals in Japan. If you haven't listened to those two podcasts I highly recommend them both! Catherine is the principal and founder of her boutique commercial law firm based in Tokyo, Catherine O'Connell Law. She is the first foreign female to set up her own law practice in Tokyo and won Tokyo Foreign Lawyer of the Year Award in 2022, Boutique Law Firm of the Year Award in 2023, and is the recipient of the Entrepreneur of the Year Award in 2020. One of Catherine's missions in life is to change the boardrooms of traditional Japan from the inside, sharing her lived experience through board coaching programs to demystify and open pathways for people to access and attain roles on Japanese corporate boards.In this episode you will hear:How Catherine went from being a tour guide in New Zealand to studying law and working as a foreign lawyer in JapanWhat motivated Catherine to set up Catherine O'Connell Law, her own law firm in TokyoAbout the lack of diversity in terms of board governance in JapanWhat Japanese companies can do now to diversify their boardsWhat women leaders can do to open boardroom doors for themselves and othersThings mentioned in the episode:Statistical Information about female board members in Japan: https://www.nikkei.co.jp/nikkeiinfo/en/global_services/nikkei-bp/female-board-member-survey-which-japanese-company-has-the-highest-percentage-of-female-board-members.htmlAbout Catherine O'Connell:Catherine O'Connell is Principal & Founder of her boutique commercial law firm based in Tokyo, Catherine O'Connell Law. She is the first foreign female to set up her own law practice in Tokyo. She won Boutique Law Firm of the Year Award 2023 and Foreign Lawyer of the Year Award 2022 and is the recipient of the Entrepreneur of the Year Award in 2020.Significantly, Catherine has been appointed in June 2023 as an Independent Audit & Supervisory Board Member of TOYOTA Motor Corporation. In June 2022 she was appointed as Outside Audit & Supervisory Board member of FUJITSU Limited. Through both of these appointments she has become the first non-Japanese female in Japanese corporate history to serve in this role on any Japanese Board. She is also Statutory Auditor on ASX-listed Japan subsidiary of CSL Behring.Catherine presides as Vice-Chair of the Australian & New Zealand Chamber of Commerce of Japan, is co-Chair of the Legal Services & IP Committee of the American Chamber of Commerce in Japan and is immediate Past President of NPO, Women in Law Japan (2021-2023).Prior to launching her law practice in 2018, Catherine was Head of Legal and APAC Regional Legal Counsel for Molex Japan LLC. She held senior In-House Legal Counsel positions Panasonic, Olympus and Mitsubishi Motors, and has extensive private practice experience at Hogan Lovells (Tokyo and London) and Anderson Lloyd (New Zealand).Catherine hosts the award-winning “Lawyer on Air” Podcast sharing inspirational stories about women working in the law in Japan and she co-hosts the “Jandals in Japan” podcast about successful New Zealand business in...

Patrick survives his first tornado warning and we've got Joana Baquero sharing education and advocacy updates on Factor 1 Deficiency and Tammy Black from the Immune Deficiency Foundation. Plus, a new Gene Therapy segment with Jim Kenny, an expert on pharmacy reimbursement.    Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information. To read “What are fibrinogen disorders?” PDF, CLICK HERE.    Tammy's documentary Compromised: Life without Immunity   Visit BEQVEZ.com to learn more about gene therapy, sign up for additional information, and listen to real patients who are now living differently.   I'm Fine is presented by @SanofiUS    Listen to the Global Hemophilia Report   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

In this episode of the Sourcing Industry Landscape Podcast, host, Dawn Tiura welcomes Dupree Jones from CSL Behring. Dupree brings over 20 years of experience in global procurement, government contracts, and vendor management, with a career that spans from managing subcontractors in Iraq to leading transformations in various industries including aerospace, retail, and pharmaceuticals. Dupree shares insights on the importance of empathy in procurement and sales. He discusses the benefits of understanding the perspectives of both buyers and suppliers, especially during challenging times like the COVID-19 pandemic. Dupree emphasizes the need for thorough research and preparation in negotiations and the positive impact of transparent communication and debriefing processes. Join us as Dupree highlights the significance of being a customer of choice, the evolving nature of procurement during global crises, and the value of maintaining professional relationships in a small, interconnected industry. This episode offers valuable advice for both seasoned professionals and those new to the field on how to foster empathy and achieve better outcomes in their procurement practices.

In this month's episode of the HAE Speaks podcast, we shine a spotlight on some of the most passionate and dedicated advocates within the Hereditary Angioedema Association (HAEA) community – our regional leaders. These individuals play a crucial role in advancing our advocacy efforts, ensuring that every voice is heard and that access to care remains a top priority. Join us for this inspiring episode as we highlight the remarkable work of our regional leaders, Cedrick, Pamela, and Kate, and the profound impact of advocacy within the HAEA community! For more information, please visit www.haea.org. A special thanks to CSL Behring and Takeda for sponsoring the 2024 HAE Speaks Podcast Series!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/GXU865. CME/MOC/NCPD/IPCE credit will be available until July 11, 2025.Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/GXU865. CME/MOC/NCPD/IPCE credit will be available until July 11, 2025.Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/GXU865. CME/MOC/NCPD/IPCE credit will be available until July 11, 2025.Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/GXU865. CME/MOC/NCPD/IPCE credit will be available until July 11, 2025.Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/GXU865. CME/MOC/NCPD/IPCE credit will be available until July 11, 2025.Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/GXU865. CME/MOC/NCPD/IPCE credit will be available until July 11, 2025.Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from CSL Behring.Disclosure information is available at the beginning of the video presentation.

On this episode, Patrick James Lynch honors the late Neil Frick, Senior VP for Medical Programs at the National Bleeding Disorders Foundation, recognizing his invaluable two-decade contribution to the bleeding disorders community. We also discuss hemophilia B gene therapy with Dr. Mark Redding, focusing on unique clinical trial designs and the role of steroids. Additionally, Makenna Dietrich shares her journey in bleeding disorder advocacy. The episode includes updates from Star Therapeutics on subcutaneous therapy for von Willebrand disease and insights on closing racial health equity gaps in the US. We also invite you to help pick a new BloodStream “theme song”.    Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   Hemophilia Uncensored Social Media: Instagram & TikTok    Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD) How the U.S. can close longstanding racial health equity gaps Visit BEQVEZ.com to learn more about gene therapy, sign up for additional information, and listen to real patients who are now living differently.   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information.   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

Check out the latest #BeyondHAE podcast episode hosted by Kobe, featuring special guest Sanyu! Diagnosed with HAE as a child, Sanyu shares the challenges she faced growing up with the condition, her experience participating in a clinical trial, and how she now manages her life as a young adult on preventative medication. This youth produced podcast is brought to you thanks to the support of the Hereditary Angioedema Association, a patient advocacy organization serving the needs of the HAE patient and caregiver community. To learn more about the HAEA and access our incredible support network, visit, ⁠⁠⁠www.haea.org⁠⁠⁠. Thank you to our sponsors CSL Behring and ⁠Takeda⁠⁠⁠.

Patrick sits down with Thomas Bartlett, Myasthenia Gravis patient and advocate, about the unique struggles of living with an invisible chronic disorder. Also, we all know if you want real answers — ask a nurse. We've got Andrea Buxton, Nurse Practitioner at the Hemophilia Outreach Center in Green Bay, WI, with her account of the first commercial dosing of gene therapy for hemophiia B.    Show Notes: Subscribe: The BloodStream Podcast   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information.   On the Shoulders of Giants Film Watch the movie and host a screening: ontheshouldersfilm.com    Beyond our Blood Watch the short films and download the facilitation guide: beyondourblood.com   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

Did you miss it? Tune in to our latest podcast episode as we bring you highlights from the Ask the Experts Q&A session at the 2023 US HAEA National Summit in Orlando, Florida. In this episode, members of the US HAEA Medical Advisory Board address pressing questions and provide invaluable insights into the challenges and advancements in the field of Hereditary Angioedema (HAE). Listen in on this informative and enlightening discussion! For more information, please visit www.haea.org. A special thanks to CSL Behring and Takeda for sponsoring the 2024 HAE Speaks Podcast Series!

In this episode, Tom Varghese, MD, FACS is joined by Jeremy Cannon, MD, SM, FACS, from the University of Pennsylvania. They discuss Dr Cannon's Excelsior Surgical Society Presidential Address, emphasizing the crucial contribution of expeditionary surgical leaders in World War II and how their legacy serves as an example for military and civilian surgeons seeking to lead in austere settings today.   Disclosure Information: Dr Varghese has nothing to disclose. Dr Cannon received royalties from UpToDate for authoring an article on an unrelated topic. Dr Cannon's institute was supported by funding from CSL Behring.   To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date.   Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more.   #JACSOperativeWord

Our blood brother buds, Clive Smith & Laurence Woollard join us today to share the latest from the ongoing saga of UK Blood Inquiry, plus our latest Gene Therapy segment has Mason Buxton's story (the first hemophilia B patient to be commercially dosed with gene therapy!).    Show Notes: Subscribe: The BloodStream Podcast   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information.   On the Shoulders of Giants Film Watch the movie and host a screening: ontheshouldersfilm.com    Beyond our Blood Watch the short films and download the facilitation guide: beyondourblood.com   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter

Want to become more heart-centered? There's a new playbook in town! Deb has released her first book The Heart-Centered Leadership Playbook: How to Master the Art of Heart in Life & Leadership. Available in ebook

We have newly appointed NBDF CEO, Phil Gattone with us sharing his background and his vision for the organization and community. And, we have the story of the first commercially dosed patient of hemophilia B gene therapy. Hear from Jamison Buxton, the father of the patient…who also happens to be the director of the HTC.  Show Notes: Subscribe: The BloodStream Podcast   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information.   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Join renowned pulmonologists Klaus Rabe, MD, PhD, FERS, and Ian Pavord, DM, FRCP, FERS, as they discuss on-treatment clinical remission as a goal in asthma management beyond disease control, and highlight the role of type 2 inflammatory biomarkers in optimizing patient outcomes. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci has received honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.  Klaus Rabe, MD, PhD has served on FDA and EMA panels for registration of drug for COPD. He has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Sanofi & Regeneron, Berlin Chemie, Novartis, GlaxoSmithKline, Insmed, CSL Behring making asthma and COPD drugs, and participated in clinical trials. He has never worked with the tobacco industry (and never will). He has no shares or proprietary interests of any kind. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303834 V1 02/2024 MAT-US-2402193 v1.0 - P Expiration Date: 02/26/2026

NBFD landed a new CEO, and HFA has responded to recent organizational changes; plus, we hear from Dr. Mark Reding and Dr. Steven Pipe about their excitement over gene therapy being added to the treatment landscape in hemophilia. We close with @theHemeNP, Maya Bloomberg talkin' Rare Disease Day.   Show Notes: Subscribe: The BloodStream Podcast   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information. Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

It's a New Year and BloodStream is back with a terrific episode. Major changes at @HFA leave Patrick wondering about the future of one of our beloved national organizations and we have folks from the FAIR initiative and CHES to share their 2024 vision for the women in bleeding disorders movement (heck yeah!). Plus, a brand new segment this year on gene therapy (whoo!) - all this and more!   Show Notes: Subscribe: The BloodStream Podcast   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Join the Movement - Equity for Women with Bleeding Disorders FAIR Coalition CHES - Programs for Women with Bleeding Disorders   Take Action Today! - Click HERE   It's a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit BeyondHemB.com or download B SUPPORT wherever you get your apps for more information. Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter   

**This conversation includes the topics of suicidal and self-harm ideation. We understand that not everyone is capable of hearing such conversations. Viewer discretion is advised.** This episode of the IDF Podcast is presented with support from Takeda, Horizon Therapeutics, CSL Behring, and Grifols. On this episode of The IDF Podcast, we turned to six young people who are longtime volunteers, Cassie Mummert, Darcy Gott, Ethan McGrew, Jesse McCall, Lance McCall, and Victoria Medl to discuss how they navigate the stress of college, postgraduate studies, and mental wellness with primary immunodeficiency. The information, terminology, and opinions presented in this forum do not necessarily reflect the views of IDF, its Board of Trustees, sponsors, or donors.